不眠症の市販医薬品・パイプライン医薬品（2022年更新版）：評価、臨床試験、ソーシャルメディア、競合情勢

2022年には、16の医薬品市場において7億3,000万人以上の不眠症の有病率が見込まれています。不眠症の治療薬として5つの主要な医薬品が販売されており、エーザイはこの疾患領域における主要企業です。不眠症治療薬のパイプラインは、あらゆる開発段階にある46品目で構成されており、そのうち約22％が早期開発段階にあります。また不眠症の臨床試験開発は商業スポンサーが中心で、米国は不眠症の臨床試験を実施する主要な国として浮上しています。

当レポートは、不眠症治療薬の現在および将来の競合情勢について、データに基づいた概要を提供します。

目次

目次

第1章 序文

• コンテンツ
• 調査範囲
• 表と図のリスト
• 略語

第2章 重要な調査結果

第3章 病気の情勢

• 病気の概要
• 疫学の概要
• 治療の概要

第4章 市販医薬品の評価

• 主要な市販医薬品
• 作用機序別概要
• 投与経路別概要
• 市販医薬品のプロファイルと売上予測

第5章 パイプライン医薬品評価

• フェーズIIIパイプライン医薬品
• 開発段階別の概要
• 分子タイプ別の概要
• 作用機序別概要
• 投与経路別概要
• 薬剤固有の相転移成功率（PTSR）と承認の可能性（LoA）
• 治療領域と適応症固有のPTSRおよびLoA

第6章 臨床試験の評価

• 履歴概要
• フェーズ別の概要
• ステータス別の概要
• 進行中および計画中の試験のフェーズ別の概要
• 仮想コンポーネントを使用した試行
• 地理的概要
• 地域別の単一国および多国籍試験
• 上位20のスポンサー：フェーズ別内訳
• 上位20のスポンサー：ステータス別内訳
• エンドポイントステータス別の概要
• 人種および民族別の概要
• 登録データ
• トライアルサイトの上位20か国
• 世界の上位20サイト
• 実現可能性分析：地理的概要
• 実現可能性分析：ベンチマークモデル

第7章 取引情勢

• 地域別の合併、買収、戦略的提携
• 最近の合併、買収、および戦略的提携

第8章 商業的評価

• 主要な市場の企業

第9章 先物市場カタリスト

第10章 付録

• 調査手法
• 調査手法：PTSRおよびLoA分析
• 著者について
• カスタマーサービス
• 免責事項

This reports provides a data-driven overview of the current and future competitive landscape in insomnia therapeutics.

Synopsis

• In 2022, there will be more than 730 million prevalent cases of insomnia across 16 pharmaceutical markets
• There are five leading marketed drugs for the treatment of insomnia, Eisai is a key player in the disease space
• The insomnia pipeline consists of 46 pharmaceuticals spanning all stages of development, with approximately 22% of drugs in early-stage development
• Commercial sponsors dominate clinical trial development in insomnia, with the US emerging as the key country for conducting trials in insomnia
• Deals involving licensing insomnia assets are the most common type of deal globally
• The strategy for many of the key players in the insomnia space has been to deprioritize their insomnia R&D activities

Scope

GlobalData's Insomnia Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type and Route of Administration
• Product Profiles with Sales Forecast
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the insomnia market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global insomnia market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pipeline Drugs Assessment

• 5.1 Phase III Pipeline Drugs
• 5.2 Overview by Development Stage
• 5.3 Overview by Molecule Type
• 5.4 Overview by Mechanism of Action
• 5.5 Overview by Route of Administration
• 5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 5.7 Therapy Area and Indication-specific PTSR and LoA

6 Clinical Trials Assessment

• 6.1 Historical Overview
• 6.2 Overview by Phase
• 6.3 Overview by Status
• 6.4 Overview by Phase for Ongoing and Planned Trials
• 6.5 Trials with Virtual Components
• 6.6 Geographic Overview
• 6.7 Single-Country and Multinational Trials by Region
• 6.8 Top 20 Sponsors with Breakdown by Phase
• 6.9 Top 20 Sponsors with Breakdown by Status
• 6.10 Overview by Endpoint Status
• 6.11 Overview by Race and Ethnicity
• 6.12 Enrollment Data
• 6.13 Top 20 countries for Trial Sites
• 6.14 Top 20 Sites Globally
• 6.15 Feasibility Analysis - Geographic Overview
• 6.16 Feasibility Analysis - Benchmark Models

7 Deals Landscape

• 7.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

• 8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

• 10.1 Methodology
• 10.2 Methodology - PTSR and LoA Analysis
• 10.3 About the Authors
• 10.4 Contact Us
• 10.5 Disclaimer